FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 528 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid... August 12, 2025 Breaking: Longtime Broadcast Journalist Cokie Roberts Dies At 75 September 17, 2019 New Areolar Incision Technique Leaves Almost No Scars for Breast Cancer... December 7, 2020 Can Some People with Breast Cancer Safely Skip Lymph Node Radiation? January 23, 2024 Load more HOT NEWS Bullies Make Fun Of Little Girl Over Cancer Scars, Her Mom... New Task Force Focuses on Quality of Life for AYAs with... Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas R2-ISS: an Improved and Simple Prognostic Staging System Allows Better Stratification...
